Phase 3 trial of ELI-002 in patients with KRAS-mutated pancreatic adenocarcinoma
Latest Information Update: 30 Jan 2025
Price :
$35 *
At a glance
- Drugs ELI 002 (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Registrational; Therapeutic Use
- 30 Jan 2025 New trial record
- 22 Jan 2025 According to Elicio Therapeutics media release,the company announced that it would expect to file a Biologics License Application (BLA) if supported by a planned Phase 3 trial.
- 22 Jan 2025 According to Elicio Therapeutics media release, the company announced that it has received supportive FDA feedback on key elements of the potential ELI-002 Phase 3 study design, including dose, schedule, patient population and primary endpoint analysis.